loading

Celldex Therapeutics Inc Aktie (CLDX) Neueste Nachrichten

pulisher
Jun 16, 2025

Celldex stock price target maintained at $50 by H.C. Wainwright - Investing.com Canada

Jun 16, 2025
pulisher
Jun 16, 2025

Global Personalized Cancer Vaccine Market | Immunotherapy - openPR.com

Jun 16, 2025
pulisher
Jun 16, 2025

Q2 Earnings Estimate for CLDX Issued By Lifesci Capital - Defense World

Jun 16, 2025
pulisher
Jun 15, 2025

Celldex Study Finds Most Patients Symptom-Free From Angioedema After One Year; Retail Bulls Stay Guarded - Asianet Newsable

Jun 15, 2025
pulisher
Jun 15, 2025

Celldex Therapeutics (NASDAQ:CLDX) Earns “Buy” Rating from HC Wainwright - Defense World

Jun 15, 2025
pulisher
Jun 14, 2025

Celldex Presents Data Demonstrating Profound Long Term Improvement In Angioedema In Barzolvolimab Phase 2 Study In Chronic Spontaneous Urticaria At Eaaci 2025 - MarketScreener

Jun 14, 2025
pulisher
Jun 14, 2025

Celldex Presents Data Demonstrating Profound Long Term - GlobeNewswire

Jun 14, 2025
pulisher
Jun 14, 2025

Celldex Presents Data Demonstrating Profound Long Term Improvement in Angioedema in Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI 2025 - GlobeNewswire Inc.

Jun 14, 2025
pulisher
Jun 13, 2025

Celldex Therapeutics (CLDX) Maintains "Buy" Rating with $50 Targ - GuruFocus

Jun 13, 2025
pulisher
Jun 13, 2025

Celldex Therapeutics’ SWOT analysis: barzolvolimab stock shows promise amid challenges By Investing.com - Investing.com South Africa

Jun 13, 2025
pulisher
Jun 13, 2025

Celldex Therapeutics’ SWOT analysis: barzolvolimab stock shows promise amid challenges - Investing.com

Jun 13, 2025
pulisher
Jun 13, 2025

Celldex Therapeutics Inc (CLDX) Stock: A Comprehensive 52-Week Review - investchronicle.com

Jun 13, 2025
pulisher
Jun 13, 2025

Celldex shares jump on impressive skin disorder drug data By Investing.com - Investing.com Canada

Jun 13, 2025
pulisher
Jun 13, 2025

Celldex Therapeutics (CLDX) Maintains "Buy" Rating with $50 Target | CLDX Stock News - GuruFocus

Jun 13, 2025
pulisher
Jun 13, 2025

Rein Therapeutics study on clinical hold; Beam updates sickle cell therapy data - Endpoints News

Jun 13, 2025
pulisher
Jun 13, 2025

Unusual Machines, Celldex Therapeutics, RH And Other Big Stocks Moving Higher On Friday - Benzinga

Jun 13, 2025
pulisher
Jun 13, 2025

Celldex stock maintains Overweight rating on promising CSU therapy results By Investing.com - Investing.com Canada

Jun 13, 2025
pulisher
Jun 13, 2025

Forecasting The Future: 8 Analyst Projections For Celldex Therapeutics - Benzinga

Jun 13, 2025
pulisher
Jun 13, 2025

Celldex Presents Unprecedented 76 Week Results from - GlobeNewswire

Jun 13, 2025
pulisher
Jun 12, 2025

Transcript : Celldex Therapeutics, Inc.Special Call - marketscreener.com

Jun 12, 2025
pulisher
Jun 12, 2025

Celldex Presents Phase 2 Study In Chronic Spontaneous Urticaria At Eaaci Congress 2025 - marketscreener.com

Jun 12, 2025
pulisher
Jun 12, 2025

Celldex (CLDX) Unveils Promising Data for Barzolvolimab in Treating Chronic Urticaria | CLDX Stock News - GuruFocus

Jun 12, 2025
pulisher
Jun 12, 2025

Breakthrough: Celldex CSU Drug Maintains Complete Response 7 Months After Treatment Ends - Stock Titan

Jun 12, 2025
pulisher
Jun 12, 2025

Celldex stock rating reiterated at Buy by Canaccord ahead of data release - Investing.com Nigeria

Jun 12, 2025
pulisher
Jun 11, 2025

One Celldex Therapeutics Insider Raised Stake By 40% In Previous Year - simplywall.st

Jun 11, 2025
pulisher
Jun 11, 2025

Eric Sprott buying at Silver Storm Mining (SVRS) - The Globe and Mail

Jun 11, 2025
pulisher
Jun 11, 2025

Analysts Set Expectations for CLDX FY2026 Earnings - Defense World

Jun 11, 2025
pulisher
Jun 10, 2025

Celldex Announces Upcoming Presentations of Barzolvolimab Phase 2 Data in Chronic Spontaneous Urticaria at EAACI 2025 Congress - GlobeNewswire

Jun 10, 2025
pulisher
Jun 10, 2025

Groundbreaking 76-Week Chronic Urticaria Treatment Data: Celldex's Barzolvolimab Results Coming to EAACI - Stock Titan

Jun 10, 2025
pulisher
Jun 06, 2025

Celldex Therapeutics appoints new board member By Investing.com - Investing.com South Africa

Jun 06, 2025
pulisher
Jun 06, 2025

Celldex Therapeutics Appoints Denice Torres To Board - citybiz

Jun 06, 2025
pulisher
Jun 06, 2025

Celldex Therapeutics appoints new board member - Investing.com

Jun 06, 2025
pulisher
Jun 06, 2025

Celldex Approves Equity Plan Amendment and Elects New Director - TipRanks

Jun 06, 2025
pulisher
Jun 06, 2025

Celldex Therapeutics Announces Election of Denice Torres to its Board of Directors - Yahoo Finance

Jun 06, 2025
pulisher
May 28, 2025

Prurigo Nodularis Pipeline 2025: FDA Updates, Therapy - openPR.com

May 28, 2025
pulisher
May 26, 2025

MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Boosts Stake in Celldex Therapeutics, Inc. (NASDAQ:CLDX) - Defense World

May 26, 2025
pulisher
May 23, 2025

Celldex Therapeutics’ SWOT analysis: barzolvolimab stock poised for growth By Investing.com - Investing.com South Africa

May 23, 2025
pulisher
May 23, 2025

Global Cholera Vaccines Market in 2025-2032 Detailed Study - openPR.com

May 23, 2025
pulisher
May 23, 2025

Celldex Therapeutics’ SWOT analysis: barzolvolimab stock poised for growth - Investing.com India

May 23, 2025
pulisher
May 19, 2025

BNP Paribas Financial Markets Raises Position in Celldex Therapeutics, Inc. (NASDAQ:CLDX) - Defense World

May 19, 2025
pulisher
May 13, 2025

Celldex Therapeutics Reports Increased Losses Amid R&D Expansion - TipRanks

May 13, 2025
pulisher
May 12, 2025

Morgan Stanley Cuts Celldex Therapeutics (NASDAQ:CLDX) Price Target to $43.00 - Defense World

May 12, 2025
pulisher
May 12, 2025

UBS Group Cuts Celldex Therapeutics (NASDAQ:CLDX) Price Target to $38.00 - Defense World

May 12, 2025
pulisher
May 12, 2025

The Goldman Sachs Group Cuts Celldex Therapeutics (NASDAQ:CLDX) Price Target to $31.00 - Defense World

May 12, 2025
pulisher
May 11, 2025

Hsbc Holdings PLC Takes $233,000 Position in Celldex Therapeutics, Inc. (NASDAQ:CLDX) - Defense World

May 11, 2025
pulisher
May 11, 2025

Celldex Therapeutics Q1 2025 Earnings: EPS of ($0.81) Misses Est - GuruFocus

May 11, 2025
pulisher
May 10, 2025

UBS Lowers Price Target for Celldex Therapeutics (CLDX) to $38 | - GuruFocus

May 10, 2025
pulisher
May 10, 2025

First Trust Advisors LP Trims Holdings in Celldex Therapeutics, Inc. (NASDAQ:CLDX) - Defense World

May 10, 2025
pulisher
May 09, 2025

H.C. Wainwright cuts Celldex stock price target to $50 from $80 - Investing.com Nigeria

May 09, 2025
pulisher
May 09, 2025

Celldex Therapeutics (CLDX): Analyst Lowers Price Target But Mai - GuruFocus

May 09, 2025
pulisher
May 09, 2025

Morgan Stanley Updates Price Target for Celldex Therapeutics (CL - GuruFocus

May 09, 2025
pulisher
May 09, 2025

Goldman Sachs Lowers Price Target for Celldex Therapeutics (CLDX) | CLDX Stock News - GuruFocus

May 09, 2025
pulisher
May 09, 2025

Celldex (CLDX) Target Price Reduced by Analyst Following Q1 Repo - GuruFocus

May 09, 2025
pulisher
May 09, 2025

UBS Adjusts Price Target on Celldex Therapeutics to $38 From $44, Maintains Buy Rating - marketscreener.com

May 09, 2025
pulisher
May 09, 2025

Celldex Therapeutics, Inc. (CLDX): Among the Best Cancer Stocks to Invest in for Long-Term Gain - Insider Monkey

May 09, 2025
$20.42
price down icon 1.37%
$35.45
price up icon 0.65%
$21.06
price down icon 1.92%
$101.83
price down icon 0.41%
$105.86
price down icon 0.39%
biotechnology ONC
$244.00
price down icon 3.69%
Kapitalisierung:     |  Volumen (24h):